BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 14528071)

  • 21. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.
    Varshney D; Zhou YY; Geller SA; Alsabeh R
    Am J Clin Pathol; 2004 Jan; 121(1):70-7. PubMed ID: 14750243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Her-2/neu expression in breast cancer--A comparison of different diagnostic methods.
    Benöhr P; Henkel V; Speer R; Vogel U; Sotlar K; Aydeniz B; Reiser A; Neubauer H; Tabiti K; Wallwiener D; Clare SE; Kurek R
    Anticancer Res; 2005; 25(3B):1895-900. PubMed ID: 16158923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating HER2 amplification and overexpression in breast cancer.
    Bartlett JM; Going JJ; Mallon EA; Watters AD; Reeves JR; Stanton P; Richmond J; Donald B; Ferrier R; Cooke TG
    J Pathol; 2001 Nov; 195(4):422-8. PubMed ID: 11745673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D; Di Leo A; Rouas G; Paesmans M; Ferreira-Filho F; Bernard C; Cardoso F; Verhest A; Piccart MJ; Gancberg D
    Anticancer Res; 2002; 22(4):2485-90. PubMed ID: 12174949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.
    Vang R; Cooley LD; Harrison WR; Reese T; Abrams J
    Am J Clin Pathol; 2000 May; 113(5):669-74. PubMed ID: 10800399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS; Fletcher JA
    Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas.
    Regitnig P; Schippinger W; Lindbauer M; Samonigg H; Lax SF
    J Pathol; 2004 Aug; 203(4):918-26. PubMed ID: 15258994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
    Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
    Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast.
    Sastre-Garau X; Genin P; Rousseau A; Al Ghuzlan A; Nicolas A; Fréneaux P; Rosty C; Sigal-Zafrani B; Couturier J; Thiery JP; Magdelénat H; Vincent-Salomon A
    Histopathology; 2004 Aug; 45(2):142-7. PubMed ID: 15279632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression.
    Tubbs RR; Pettay J; Roche P; Stoler MH; Jenkins R; Myles J; Grogan T
    J Mol Diagn; 2000 May; 2(2):78-83. PubMed ID: 11272892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.
    Kakar S; Puangsuvan N; Stevens JM; Serenas R; Mangan G; Sahai S; Mihalov ML
    Mol Diagn; 2000 Sep; 5(3):199-207. PubMed ID: 11070154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
    Birner P; Oberhuber G; Stani J; Reithofer C; Samonigg H; Hausmaninger H; Kubista E; Kwasny W; Kandioler-Eckersberger D; Gnant M; Jakesz R;
    Clin Cancer Res; 2001 Jun; 7(6):1669-75. PubMed ID: 11410505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
    Lebeau A; Deimling D; Kaltz C; Sendelhofert A; Iff A; Luthardt B; Untch M; Löhrs U
    J Clin Oncol; 2001 Jan; 19(2):354-63. PubMed ID: 11208826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.